Loading...
XTSX
NGEN
Market cap210mUSD
Jul 11, Last price  
3.95CAD
1D
-1.99%
1Q
40.57%
IPO
127.01%
Name

NervGen Pharma Corp

Chart & Performance

D1W1MN
No data to show
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
16.86%
Rev. gr., 5y
%
Revenues
0k
Net income
-22m
L+23.61%
-11,813-1,358,483-9,666,780-11,176,398-12,641,932-18,106,330-22,382,120
CFO
-17m
L+49.09%
0-1,040,079-8,093,960-6,306,859-8,269,157-17,784,163-11,295,594-16,841,034
Earnings
Aug 20, 2025

Profile

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.
IPO date
Mar 13, 2019
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
17,875
23,067
Unusual Expense (Income)
NOPBT
(17,875)
(23,067)
NOPBT Margin
Operating Taxes
(2,616)
Tax Rate
NOPAT
(17,875)
(20,451)
Net income
(22,382)
23.61%
(18,106)
43.22%
Dividends
Dividend yield
Proceeds from repurchase of equity
23,012
867
19,763
BB yield
-0.54%
-23.46%
Debt
Debt current
97
92
86
Long-term debt
114
303
481
Deferred revenue
Other long-term liabilities
Net debt
(17,162)
(11,265)
(21,885)
Cash flow
Cash from operating activities
(16,841)
(11,296)
(17,784)
CAPEX
(6)
(21)
Cash from investing activities
59
(139)
(21)
Cash from financing activities
22,695
766
22,641
FCF
(2,333)
(15,247)
(20,743)
Balance
Cash
17,365
11,660
22,452
Long term investments
8
Excess cash
17,373
11,660
22,452
Stockholders' equity
2,577
(2,009)
13,461
Invested Capital
106
197
283
ROIC
ROCE
986.54%
EV
Common stock shares outstanding
59,290
52,649
Price
3.14
16.30%
2.70
68.75%
1.60
-41.39%
Market cap
160,083
90.04%
84,238
-21.46%
EV
148,818
62,354
EBITDA
84
(17,730)
(22,952)
EV/EBITDA
Interest
515
Interest/NOPBT